{"id":4203,"count":2,"description":"Tuberkulose (TB)<\/strong> forbliver en af de mest d\u00f8delige infektionssygdomme globalt \u2014 WHO estimerer, at 10,6 millioner mennesker blev syge med TB i 2022, og 1,3 millioner d\u00f8de, herunder 167.000 med HIV-coinfektion. Sygdommen skyldes Mycobacterium tuberculosis<\/em>, en langsomtvoksende intracellul\u00e6r bacille, der prim\u00e6rt p\u00e5virker lungerne, men kan involvere n\u00e6sten alle organsystemer. Moderne korttidsbehandling af TB er fuldt kurativ \u2014 men kun ved korrekt anvendelse<\/strong>: den rigtige kombination af l\u00e6gemidler, i den rigtige dosis, for den fulde varighed, under specialistvejledning. Denne side viser de anti-tuberkul\u00f8se l\u00e6gemidler, der er p\u00e5 lager hos MedsBase. Dette er ikke en selvbehandlingsvejledning for aktiv TB.<\/strong>\nThe 4-drug RIPE regimen\nThe WHO standard regimen for new, drug-susceptible pulmonary tuberculosis is six months in two phases:\nIntensiv fase \u2014 2 m\u00e5neder:<\/strong> Rifampicin + Isoniazid + Pyrazinamid + Ethambutol<\/strong> (RIPE), alle fire l\u00e6gemidler dagligt.Kontinueringsfase \u2014 4 m\u00e5neder:<\/strong> Rifampicin + Isoniazid (RH), continued daily.\nLonger regimens (9–12 months) apply to TB meningitis, bone and joint TB, and disseminated disease. Treatment is supervised — direkte observeret terapi (DOT)<\/strong> is recommended in most national programmes to ensure adherence and to prevent the emergence of multidrug-resistant TB (MDR-TB).\nWhy combination therapy is mandatory\nSingle-agent treatment of active TB inevitably selects for resistant organisms. The bacterial load in a cavitating pulmonary lesion is enormous (up to 109 bacilli) and naturally occurring resistance mutations exist at low frequency for every drug. Using one drug kills the susceptible majority and leaves the resistant minority to multiply — treatment failure with a now-untreatable strain. Kombinationsbehandling<\/strong> virker, fordi sandsynligheden for, at \u00e9n organisme samtidigt er resistent over for flere l\u00e6gemidler, er ekstremt lille. Derfor indeholder hver side i denne kategori en eksplicit advarsel om, at k\u00f8b af kun \u00e9t middel kun er hensigtsm\u00e6ssigt kun<\/strong> for ongoing supervised regimen continuation, latent TB infection (4-month rifampicin monotherapy), or specific non-TB indications such as leprosy, MAC, or meningococcal prophylaxis.\nMultidrug-resistant TB — a warning\nMDR-TB — resistance to at least rifampicin and isoniazid — affected an estimated 410,000 people worldwide in 2022. MDR-TB requires longer treatment (9–20 months) with second-line agents including fluorokinoloner<\/strong> (levofloxacin, moxifloxacin), linezolid<\/strong>, bedaquilin<\/strong>, og clofazimin<\/strong>. MDR-TB is the predictable downstream result of partial, irregular, or single-agent treatment of drug-susceptible TB. Cure is possible but harder, more expensive, and more toxic than first-line therapy — the case for getting the initial regimen right and completing it.\nAnti-TB medications stocked at MedsBase\nThis category currently lists to af de fire f\u00f8rste-r\u00e6kkes midler<\/strong>:\nR-Cin<\/strong><\/a> \u2014 rifampicin 300\/450\/600 mg<\/strong> (Cipla). Det vigtigste steriliserende middel i TB-terapi. Bruges ogs\u00e5 som 4-m\u00e5neders monoterapi for latent TB-infektion (4R-regime), i multibacill\u00e6r lepra med flermiddelbehandling, til meningokok-kontaktprofylakse og ved alvorlige stafylokok-infektioner i knogler, led eller proteser. Rifampicin er en st\u00e6rk CYP3A4 \/ CYP2C9 \/ CYP2C19-inducer<\/strong> \u2014 det reducerer effektiviteten af snesevis af samtidigt administrerede l\u00e6gemidler inklusive orale pr\u00e6ventionsmidler, warfarin, DOAC'er, statiner, metadon, transplantationsimmunsuppressiva, antiretrovirale midler og mange andre. Oplys altid om alle samtidige medicineringer f\u00f8r p\u00e5begyndelse.<\/strong> For\u00e5rsager orange-r\u00f8d misfarvning af urin, sved, t\u00e5rer og spyt (ufarligt, men farver bl\u00f8de kontaktlinser permanent).Combutol<\/strong><\/a> \u2014 ethambutol HCl 200\/400\/800 mg<\/strong> (Lupin). En bakteriostatisk agent, hvis rolle i behandlingen er at undertrykke udviklingen af resistens over for de baktericide partnerl\u00e6gemidler. Ogs\u00e5 en kerneagent for Mycobacterium avium complex (MAC)-infektion ved HIV. Den afg\u00f8rende toksicitet er dosisafh\u00e6ngig optisk neuritis<\/strong>: tab af synsskarphed og r\u00f8d-gr\u00f8n farveopfattelse, som regel reversibel, hvis l\u00e6gemidlet stoppes ved det f\u00f8rste symptom, men potentielt permanent, hvis det ikke g\u00f8res. Baseline oftalmologisk vurdering + m\u00e5nedlige synskontroller er obligatoriske.<\/strong> Renal-dose adjustment is essential.\nThe other two first-line agents — isoniazid<\/strong> og pyrazinamid<\/strong> — are not currently stocked at MedsBase. Patients on a full RIPE regimen will need to source these from another supplier, a hospital pharmacy, or their national TB programme. National TB programmes in most countries provide first-line TB drugs free of charge.\nMandatory monitoring during TB therapy\nLeverfunktion<\/strong> \u2014 baseline og mindst m\u00e5nedligt. Rifampicin, isoniazid og pyrazinamid er alle hepatotoksiske; den kombinerede behandling for\u00e5rsager klinisk signifikant hepatitis hos cirka 5% af patienterne. Stop behandlingen og s\u00f8g l\u00e6ge ved gulsot, m\u00f8rk urin eller smerter i h\u00f8jre \u00f8verste kvadrant.Synsskarphed og farvesyn<\/strong> \u2014 baseline og m\u00e5nedligt mens du er p\u00e5 ethambutol. Stop ethambutol samme dag ved nye synsproblemer.Sputumpr\u00f8ve og kultur<\/strong> \u2014 den prim\u00e6re effektmark\u00f8r for aktiv pulmonal TB; konvertering til negativ kultur inden for 2 m\u00e5neder indikerer en god respons.Nyrefunktion og serum urinsyre<\/strong> \u2014 ethambutol cleares via nyrerne; pyrazinamide \u00f8ger urinsyren og kan udl\u00f8se gigt.HIV-status<\/strong> — TB-HIV co-infection alters the regimen, the drug interactions, and the prognosis. Every patient with active TB should be offered HIV testing.\nWho this category is not for\nIf you have suspected active TB (chronic cough > 3 weeks, weight loss, night sweats, blood-stained sputum) you need a TB specialist, sputum testing, susceptibility testing, contact tracing, and combination therapy under directly observed treatment — ikke selvbehandling med enkeltstof<\/strong>. Ubehandlet eller delvist behandlet aktiv TB er smitsom, dr\u00e6ber cirka halvdelen af de inficerede og er den mest almindelige \u00e5rsag til MDR-TB. Brug denne side til genopfyldning og forts\u00e6ttelse af en eksisterende overv\u00e5get behandlingsplan, til behandling af latent TB-infektion eller til de specifikke ikke-TB-indikationer, der er angivet p\u00e5 hvert produktblad.","link":"https:\/\/medsbase.com\/da\/tuberculosis-treatment\/","name":"Behandling af tuberkulose","slug":"tuberculosis-treatment","taxonomy":"product_cat","parent":3223,"meta":[],"menu_order":0,"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product_cat\/4203","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product_cat"}],"about":[{"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/taxonomies\/product_cat"}],"up":[{"embeddable":true,"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product_cat\/3223"}],"wp:post_type":[{"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product?product_cat=4203"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}